ArticleLeukemia2013
miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.
Article in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 54 citations in OpenAlex.
- Review
- From mechanisms to therapies: the multifaceted roles of guanylate-binding protein 2 in immunity, cancer, and beyond.Frontiers in immunology · 2025Review
- Small extracellular vesicles derived from acute myeloid leukemia cells promote leukemogenesis by transferring miR-221-3p.Haematologica · 2024Article
- Insight into microRNAs' involvement in hematopoiesis: current standing point of findings.Stem cell research & therapy · 2023Review
- Profiling of extracellular vesicle-bound miRNA to identify candidate biomarkers of chronic alcohol drinking in nonhuman primates.Alcoholism, clinical and experimental research · 2022Article
- Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators ofFrontiers in genetics · 2022Article
- Relationship between miRNA-433 and SPP1 in the presence of fracture and traumatic brain injury.Experimental and therapeutic medicine · 2021Article
- LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis.Bioscience reports · 2020Observational
- Do exosomes play role in cardiovascular disease development in hematological malignancy?Molecular biology reports · 2020Review
- Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease.The Journal of experimental medicine · 2019Review
- MicroRNAs: Fine Tuners of Monocyte Heterogeneity.Frontiers in immunology · 2019Review
- Kinetics of the chromosome 14 microRNA cluster ortholog and its potential role during placental development in the pregnant mare.BMC genomics · 2018Article
- A CREB1/miR-433 reciprocal feedback loop modulates proliferation and metastasis in colorectal cancer.Aging · 2018Article
- Effects of Brain-Derived Neurotrophic Factor on MicroRNA Expression Profile in Human Endothelial Progenitor Cells.Cell transplantation · 2018Article
- Reduced miR-433 expression is associated with advanced stages and early relapse of colorectal cancer and restored miR-433 expression suppresses the migration, invasion and proliferation of tumor cellsOncology letters · 2018Article
- Comparative transcriptome analysis to investigate the potential role of miRNAs in milk protein/fat quality.Scientific reports · 2018Article
- Molecular regulation of follicle-stimulating hormone synthesis, secretion and action.Journal of molecular endocrinology · 2018Review
- Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.PloS one · 2018Article
- MicroRNA-433 regulates apoptosis by targeting PDCD4 in human osteosarcoma cells.Oncology letters · 2017Article
- Roles of differential expression of microRNA-21-3p and microRNA-433 in FSH regulation in rat anterior pituitary cells.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
BCR-ABL-negative myeloproliferative neoplasms (MPNs) are most frequently characterized by the JAK2V617F gain-of-function mutation, but several studies showed that JAK2V617F may not be the initiating event in MPN development, and recent publications indicate that additional alterations such as chromatin modification and microRNA (miRNA) deregulation may have an important role in MPN pathogenesis. Here we report that 61 miRNAs were significantly deregulated in CD34+ cells from MPN patients compared with controls (P<0.01). Global miRNA analysis also revealed that polycythemia vera (JAKV617F) and essential thrombocythemia (JAK2 wild type) patients have significantly different miRNA expression profiles from each other. Among the deregulated miRNAs, expression of miR-134, -214 and -433 was not affected by changes in JAK2 activity, suggesting that additional signaling pathways are responsible for the deregulation of these miRNAs in MPN. Despite its upregulation in MPN CD34+ and during normal erythropoiesis, both overexpression and knockdown studies suggest that miR-433 negatively regulates CD34+ proliferation and differentiation ex vivo. Its novel target GBP2 is downregulated during normal erythropoiesis and regulates proliferation and erythroid differentiation in TF-1 cells, indicating that miR-433 negatively regulates hematopoietic cell proliferation and erythropoiesis by directly targeting GBP2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.